Research and Markets has announced the addition of the "Global Wilson's Disease Market: Industry Analysis & Outlook" report to their offering.
Wilson's disease is a rare, congenital disorder which is also known as hepatolenticular degeneration and is named after Kinnear Wilson who was the first to describe this disorder in 1912. Wilson's disease is an inherited condition that leads to excessive accumulation of copper in vital organs such as the liver, brain, etc.
Wilson's disease is caused by the alteration of a gene named ATP7B. This mutation prevents the liver from disposing of the accumulated copper from the body as a healthy liver should. Eventually, copper is released into the bloodstream and it gets deposited in other organs, especially the brain, kidneys, and cornea. When diagnosed early, Wilson's disease is treatable. Even though the treatment is life-long, if patients stay on drugs and are compliant to it, they can basically experience a normal life expectancy.
The major factors that are expected to drive the market include rising prices of chelators in the US, rising attractiveness of orphan drugs market, increasing global healthcare expenditure as well as spending on medicines. The significant trends in the market comprise falling number of prescriptions for Wilson's disease, and the development of gene therapy as a potential cure for the disease. However, the market is threatened by critical challenges such as under-diagnosis of the disease, lack of safety in treatments, poor compliance to current treatments and unmet efficacy needs.
The research report provides a comprehensive study of global Wilson's disease market performance at present and future outlook and also an in-depth study of its major regional markets such as those in Europe and the US. Furthermore, market dynamics such as key trends and development; and challenges are examined in depth.
Key Topics Covered:
1. Market Overview
2. Global Market
3. Regional Markets
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/wn2345/global_wilsons
Related Topics: Central Nervous System Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005896/en/Business Wire
Last updated on: 15/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.